北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
作者: Jiang, Qian; Xu, Lan-Ping; Liu, Dai-Hong; Liu, Kai-Yan; Chen, Shan-Shan; Jiang, Bin; Jiang, Hao; Chen, Huan; Chen, Yu-Hong; Han, Wei; Zhang, Xiao-Hui; Wang, Yu; Qin, Ya-Zhen; Liu, Yan-Rong; Lai, Yue-Yun; Huang, Xiao-Jun
刊名: BLOOD
发表日期: 2011-03-17
DOI: 10.1182/blood-2010-09-308510
卷: 117, 期:11, 页:3032-3040
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: CHRONIC MYELOID-LEUKEMIA ; ABL TYROSINE KINASE ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; WORLD-HEALTH-ORGANIZATION ; MARROW-TRANSPLANTATION ; CYTOGENETIC RESPONSES ; BLAST CRISIS ; FOLLOW-UP ; PHILADELPHIA-CHROMOSOME ; WORKING PARTY
英文摘要:

The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) versus allo-HSCT (n = 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 months, hemoglobin < 100 g/L, and peripheral blood blasts > 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with 6-year event-free survival (EFS), OS, and PFS rates of more than 80.0%. Intermediate-risk (any factor) patients showed no difference in EFS and OS, but 6-year PFS rates were 55.7% versus 92.9% (P = .047) with imatinib versus allo-HSCT, respectively. Among high-risk (at least 2 factors) patients, imatinib was by far inferior to allo-HSCT, with 5-year EFS, OS, and PFS rates of 9.3% versus 66.7% (P = .034), 17.7% versus 100% (P = .008), and 18.8% versus 100% (P = .006), respectively. We conclude that allo-HSCT confers significant survival advantages for high-and intermediate-risk patients with AP-CML compared with imatinib treatment; however, the outcomes of the 2 therapies are equally good in low-risk patients. All trials were registered with the Chinese Clinical Trial Registry (www.chictr.org) as CHiCTR-TNC-10000955. (Blood. 2011; 117(11): 3032-3040)

语种: 英语
所属项目编号: 30725038 ; IRT0702
项目资助者: National Outstanding Young Scientists&prime ; Foundation of China ; University of China
WOS记录号: WOS:000288496300012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53542
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Jiang, Qian,Xu, Lan-Ping,Liu, Dai-Hong,et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase[J]. BLOOD,2011,117(11):3032-3040.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Qian]'s Articles
[Xu, Lan-Ping]'s Articles
[Liu, Dai-Hong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Qian]‘s Articles
[Xu, Lan-Ping]‘s Articles
[Liu, Dai-Hong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace